CoChat

Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: A Randomized Phase II Study of the First Triple-Combination Drug

Open access

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index; 4 of the 66 sources its claims cite were checked for support.

Abstract

BACKGROUND: A three-pronged approach to acne treatment-combining an antibiotic, antibacterial, and retinoid-could provide greater efficacy and tolerability than single or dyad treatments, while potentially improving patient compliance and reducing antibiotic resistance. OBJECTIVES: We aimed to evaluate the efficacy and safety of triple-combination, fixed-dose topical clindamycin phosphate 1.2%/benzoyl peroxide (BPO) 3.1%/adapalene 0.15% (IDP-126) gel for the treatment of acne. METHODS: In a phase II, double-blind, multicenter, randomized, 12-week study, eligible participants aged ≥ 9 years with moderate-to-severe acne were equally randomized to once-daily IDP-126, vehicle, or one of three component dyad gels: BPO/adapalene; clindamycin phosphate/BPO; or clindamycin phosphate/adapalene. Coprimary endpoints were treatment success at week 12 (participants achieving a ≥ 2-grade reduction from baseline in Evaluator's Global Severity Score and clear/almost clear skin) and least-squares mean absolute changes from baseline in inflammatory and noninflammatory lesion counts to week 12. Treatment-emergent adverse events and cutaneous safety/tolerability were also assessed. RESULTS: A total of 741 participants were enrolled. At week 12, 52.5% of participants achieved treatment success with IDP-126 vs vehicle (8.1%) and dyads (range 27.8-30.5%; P ≤ 0.001, all). IDP-126 also provided significantly greater absolute reductions in inflammatory (29.9) and noninflammatory (35.5) lesions compared with vehicle or dyads (range inflammatory, 19.6-26.8; noninflammatory, 21.8-30.0; P < 0.05, all), corresponding to > 70% reductions with IDP-126. IDP-126 was well tolerated, with most treatment-emergent adverse events of mild-to-moderate severity. CONCLUSIONS: Once-daily treatment with the novel fixed-dose triple-combination clindamycin phosphate 1.2%/BPO 3.1%/adapalene 0.15% gel demonstrated superior efficacy to vehicle and all three dyad component gels, and was well tolerated over 12 weeks in pediatric, adolescent, and adult participants with moderate-to-severe acne. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov identifier NCT03170388 (registered 31 May, 2017).

Overview

CoChat Summary

TL;DR

In a phase II, double-blind, randomized, 12-week trial, fixed-dose clindamycin phosphate 1.2%/benzoyl peroxide 3.1%/adapalene 0.15% gel (IDP-126) was superior to vehicle and all three component dyad gels for moderate-to-severe acne. IDP-126 was well tolerated, with most treatment-emergent adverse events mild to moderate.

Key findings

  • At week 12, 52.5% of IDP-126-treated participants achieved treatment success versus 8.1% with vehicle and 27.8–30.5% with the three dyad gels (P ≤ 0.001 for all comparisons).
  • IDP-126 produced greater absolute reductions from baseline in inflammatory lesions (29.9) and noninflammatory lesions (35.5) than vehicle or dyads (inflammatory range 19.6–26.8; noninflammatory range 21.8–30.0; P < 0.05 for all), corresponding to >70% reductions.
  • Treatment-emergent adverse events were mostly mild or moderate; discontinuations due to treatment-emergent adverse events occurred in 0–5.3% across treatments, with the highest rate in the BPO/adapalene group.
  • Four participants had one serious adverse event each, none considered related to treatment.

Methods

  • Phase II, multicenter, randomized, double-blind, parallel-group, vehicle-controlled study at 31 US and 4 Canadian centers; participants aged ≥9 years with moderate (EGSS 3) or severe (EGSS 4) acne were equally randomized to once-daily IDP-126, vehicle, or one of three component dyad gels for 12 weeks.
  • Coprimary endpoints were treatment success at week 12 (≥2-grade EGSS reduction plus clear/almost clear) and absolute changes from baseline to week 12 in inflammatory and noninflammatory lesion counts.
  • Treatment success used logistic regression; lesion count changes used rank-transformed ANCOVA with multiple imputation for missing efficacy data; 741 participants were randomized, 740 were in the intent-to-treat population, and 725 were in the safety population.

Limitations

  • The paper states that EGSS assessments may have inter-observer bias or variation, treatment duration was limited to 12 weeks, and results may not be generalizable to diverse real-world practice populations differing in race, age, and sex.
  • The paper states that exclusion of component monads prevented determination of each active treatment’s direct contribution and calculation of synergistic treatment effect.
  • The paper states that no head-to-head or facial-splitting studies were conducted against other approved dyad treatments, and no formal sample size calculation was performed.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1007/s40257-021-00650-3

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Participant disposition. aWithdrawal by parent or guardian. bOne excluded participant was not dispensed the study drug. cExcluded participants had no post-baseline safety evaluations. ADAP adapalene 0.15%, BPO benzoyl peroxide 3.1%, CLIN clindamycin phosphate 1.2%, IDP-126 clindamycin phosphate 1.2%/benzoyl peroxide 3.1%/adapalene 0.15%, ITT intent to treat
Fig. 1 Participant disposition. aWithdrawal by parent or guardian. bOne excluded participant was not dispensed the study drug. cExcluded participants had no post-baseline safety evaluations. ADAP adapalene 0.15%, BPO benzoyl peroxide 3.1%, CLIN clindamycin phosphate 1.2%, IDP-126 clindamycin phosphate 1.2%/benzoyl peroxide 3.1%/adapalene 0.15%, ITT intent to treatCC BY-NC · PubMed Central
Fig. 2 Least-squares (LS) mean percent reductions in a inflammatory lesions and b noninflammatory lesions (intent-to-treat [ITT] population). Multiple imputation was used to impute missing values. *P < 0.05; ***P < 0.001 vehicle vs clindamycin phosphate 1.2%/benzoyl peroxide 3.1%/adapalene 0.15% (IDP-126). Data not shown: P-values for IDP-126 vs dyads were significant (P < 0.05) as follows: inflammatory lesions: benzoyl peroxide 3.1%, (BPO)/adapalene 0.15% (ADAP) at weeks 2, 4, 8, and 12; clindamycin phosphate 1.2%, (CLIN)/BPO at weeks 4 and 12; CLIN/ADAP at weeks 4, 8, and 12. Noninflammatory lesions: BPO/ADAP at weeks 8 and 12; CLIN/BPO at weeks and weeks 4, 8, and 12; CLIN/ADAP at weeks 4, 8, and 12. All active dyad treatments were significant vs vehicle at weeks 8 and 12 for both inflammatory and noninflammatory lesions (P < 0.01, all); additionally, CLIN/BPO and CLIN/ADAP were significant vs vehicle at weeks 2 and 4 for inflammatory lesions (P < 0.05, all) and BPO/ADAP and CLIN/ADAP were significant vs vehicle at week 4 for noninflammatory lesions (P < 0.01, both)
Fig. 2 Least-squares (LS) mean percent reductions in a inflammatory lesions and b noninflammatory lesions (intent-to-treat [ITT] population). Multiple imputation was used to impute missing values. *P < 0.05; ***P < 0.001 vehicle vs clindamycin phosphate 1.2%/benzoyl peroxide 3.1%/adapalene 0.15% (IDP-126). Data not shown: P-values for IDP-126 vs dyads were significant (P < 0.05) as follows: inflammatory lesions: benzoyl peroxide 3.1%, (BPO)/adapalene 0.15% (ADAP) at weeks 2, 4, 8, and 12; clindamycin phosphate 1.2%, (CLIN)/BPO at weeks 4 and 12; CLIN/ADAP at weeks 4, 8, and 12. Noninflammatory lesions: BPO/ADAP at weeks 8 and 12; CLIN/BPO at weeks and weeks 4, 8, and 12; CLIN/ADAP at weeks 4, 8, and 12. All active dyad treatments were significant vs vehicle at weeks 8 and 12 for both inflammatory and noninflammatory lesions (P < 0.01, all); additionally, CLIN/BPO and CLIN/ADAP were significant vs vehicle at weeks 2 and 4 for inflammatory lesions (P < 0.05, all) and BPO/ADAP and CLIN/ADAP were significant vs vehicle at week 4 for noninflammatory lesions (P < 0.01, both)CC BY-NC · PubMed Central
Fig. 3 Acne improvements with clindamycin phosphate 1.2%/benzoyl peroxide 3.1%/adapalene 0.15% (IDP-126). Individual results may vary. EGSS Evaluator’s Global Severity Score (0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, 4 = severe)
Fig. 3 Acne improvements with clindamycin phosphate 1.2%/benzoyl peroxide 3.1%/adapalene 0.15% (IDP-126). Individual results may vary. EGSS Evaluator’s Global Severity Score (0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, 4 = severe)CC BY-NC · PubMed Central
Fig. 4 Acne-Specific Quality of Life Questionnaire at week 12 (intent-to-treat population). No imputation of missing values. Higher scores for each domain reflect improved health-related quality of life. Self-perception domain assesses the extent facial acne has affected a particular area of self-perception (e.g., feeling self-conscious, feeling unattractive, dissatisfaction with self-appearance). Role-emotional domain assesses the emotional effect or impact of facial acne (e.g., annoyance at spending time on face, worry/concern about medications working fast enough, bothersomeness of needing cover-up). Role-social domain assesses the impact of facial acne on a respondent’s intersocial relationships (e.g., going out in public, meeting new people, socializing). Acne symptoms assesses the physical symptoms experienced by facial acne (e.g., bumps on face, scabbing, worry about scarring); the acne symptom domain score correlates inversely with acne severity. ADAP adapalene 0.15%, BPO benzoyl peroxide 3.1%, CLIN clindamycin phosphate 1.2%, IDP-126 clindamycin phosphate 1.2%/benzoyl peroxide 3.1%/adapalene 0.15%
Fig. 4 Acne-Specific Quality of Life Questionnaire at week 12 (intent-to-treat population). No imputation of missing values. Higher scores for each domain reflect improved health-related quality of life. Self-perception domain assesses the extent facial acne has affected a particular area of self-perception (e.g., feeling self-conscious, feeling unattractive, dissatisfaction with self-appearance). Role-emotional domain assesses the emotional effect or impact of facial acne (e.g., annoyance at spending time on face, worry/concern about medications working fast enough, bothersomeness of needing cover-up). Role-social domain assesses the impact of facial acne on a respondent’s intersocial relationships (e.g., going out in public, meeting new people, socializing). Acne symptoms assesses the physical symptoms experienced by facial acne (e.g., bumps on face, scabbing, worry about scarring); the acne symptom domain score correlates inversely with acne severity. ADAP adapalene 0.15%, BPO benzoyl peroxide 3.1%, CLIN clindamycin phosphate 1.2%, IDP-126 clindamycin phosphate 1.2%/benzoyl peroxide 3.1%/adapalene 0.15%CC BY-NC · PubMed Central

Verification

Claims the paper makes

3 Valid · 1 Not valid · 31 Not checked · 82 Own results and interpretations

58 more claims

Create a free account to see all 117 claims and to verify the 62 references still open.

See all claims — free account
  • The quote only partly states this claim. 5
  • Probably not a substantial claim. 36
  • It may state two separate claims as one. 27

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 31 references

Cited by

See all 57

Metadata

Authors
Stein Gold, L., Baldwin, H., Kircik, L. H., Weiss, J. S., Pariser, D. M., Callender, V., Lain, E., Gold, M., Beer, K., Draelos, Z., Sadick, N., Pillai, R., Bhatt, V., & Tanghetti, E. A.
Affiliations
  • Robert Wood Johnson University Hospital (US)
  • Indiana University School of Medicine (US)
  • Eastern Virginia Medical School (US)
  • Howard University (US)
  • Tennessee Clinical Research Center (US)
  • University of Miami (US)
  • Dermatology Consulting Services (US)
  • Sadick Dermatology (US)
  • Bausch Health (United States) (US)
  • Center for Dermatology and Laser Surgery (US)
Venue
American Journal of Clinical Dermatology
Published
2021-10-21
Volume
23
Issue
1
Pages
93-104
ISSN
  • 1175-0561 (ISSN-L)
  • 1179-1888
OpenAlex
W3206427606
Cited by
51
References
31
Citations by year
2026: 8 · 2025: 16 · 2024: 15 · 2023: 6 · 2022: 6
FWCI
6.00
Type
journal article
Language
en
Open access
Licence
Locations
  • American Journal of Clinical Dermatology (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • IUScholarWorks (Indiana University) (submittedVersion, cc-by-nc)
Funders
  • Ortho Dermatologics
  • Bausch Health
Topics
  • Health Sciences › Medicine › Dermatology › Acne and Rosacea Treatments and Effects
  • Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
  • Health Sciences › Medicine › Dermatology › Dermatologic Treatments and Research
Keywords
acne, clindamycin phosphate, benzoyl peroxide, adapalene, moderate to severe acne, safety and tolerability, antibiotic resistance, retinoids, antibacterial agents, medication adherence, pediatric acne
MeSH terms
Adapalene, Acne Vulgaris, Administration, Topical, Adolescent, Adult, Benzoyl Peroxide, Child, Clindamycin, Dermatologic Agents, Double-Blind Method, Drug Combinations, Female, Humans, Male, Middle Aged, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-01, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-01 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: A Randomized Phase II Study of the First Triple-Combination Drug. https://app.cochat.ai/papers/10.1007/s40257-021-00650-3
The paper
Stein Gold, L., Baldwin, H., Kircik, L. H., Weiss, J. S., Pariser, D. M., Callender, V., Lain, E., Gold, M., Beer, K., Draelos, Z., Sadick, N., Pillai, R., Bhatt, V., & Tanghetti, E. A. (2022). Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: A Randomized Phase II Study of the First Triple-Combination Drug. American Journal of Clinical Dermatology. https://doi.org/10.1007/s40257-021-00650-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.